Using foci number to predict central lymph node metastases of papillary thyroid microcarcinomas with multifocality

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 6, 2015, Pages 9925-9930

  Guo, Yawen ^a   Liu, Zeming ^a   Yu, Pan ^a   Liu, Chunping ^a   Ming, Jie ^a   Zhang, Ning ^a   Yusufu, Maimaiti ^a   Chen, Chen ^a   Huang, Tao ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Lymph node; Metastases; Number of foci; Papillary thyroid carcinoma

Indexed keywords

ADULT; AGE; ARTICLE; CANCER PROGNOSIS; CLINICAL FEATURE; FEMALE; HASHIMOTO DISEASE; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PAPILLARY THYROID MICROCARCINOMA; PROGNOSIS; RISK FACTOR; SEX; THYROID CARCINOMA; THYROIDECTOMY; TUMOR INVASION; TUMOR VOLUME;

EID: 84938322737     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. [1] Kutler DI, Crummey AD and Kuhel WI. Routine central compartment lymph node dissection for patients with papillary thyroid carcinoma. Head Neck 2012; 34: 260-263.
2. [2] Zhao Q, Ming J, Liu C, Shi L, Xu X, Nie X and Huang T. Multifocality and total tumor diameter predict central neck lymph node metastases in papillary thyroid microcarcinoma. Ann Surg Oncol 2013; 20: 746-752.
3. [3] Riss JC, Peyrottes I, Chamorey E, Haudebourg J, Sudaka A, Benisvy D, Marcy PY, Nao EE, Demard F, Vallicioni J, Poissonnet G, Da-ssonville O, Santini J and Bozec A. Prognostic impact of tumour multifocality in thyroid papillary microcarcinoma based on a series of 160 cases. Eur Ann Otorhinolaryngol Head Neck Dis 2012; 129: 175-178.
4. [4] Liu Z, Xun X, Wang Y, Mei L, He L, Zeng W, Wang CY and Tao H. MRI and ultrasonography detection of cervical lymph node metastases in differentiated thyroid carcinoma before reoperation. Am J Transl Res 2014; 6: 147-154.
5. [5] Ito Y, Nikiforov YE, Schlumberger M and Vigneri R. Increasing incidence of thyroid cancer: controversies explored. Nat Rev Endocrinol 2013; 9: 178-184.
6. [6] Pisanu A, Saba A, Podda M, Reccia I and Uccheddu A. Nodal metastasis and recurrence in papillary thyroid microcarcinoma. Endocrine 2015; 48: 575-581.
7. [7] Liu Z, Li X, Shi L, Maimaiti Y, Chen T, Li Z, Wang S, Xiong Y, Guo H, He W, Liu C, Nie X, Zeng W and Huang T. Cytokeratin 19, thyroperoxidase, HBME-1 and galectin-3 in evaluation of aggressive behavior of papillary thyroid carcinoma. Int J Clin Exp Med 2014; 7: 2304-2308.
8. [8] Hay ID, Hutchinson ME, Gonzalez-Losada T, McIver B, Reinalda ME, Grant CS, Thompson GB, Sebo TJ and Goellner JR. Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery 2008; 144: 980-987; discussion 987-988.
9. [9] Mercante G, Frasoldati A, Pedroni C, Formisano D, Renna L, Piana S, Gardini G, Valcavi R and Barbieri V. Prognostic factors affecting neck lymph node recurrence and distant metastasis in papillary microcarcinoma of the thyroid: results of a study in 445 patients. Thyroid 2009; 19: 707-716.
10. [10] Liu Z, Wang L, Yi P, Wang CY and Huang T. Risk factors for central lymph node metastasis of patients with papillary thyroid microcarcinoma: a meta-analysis. Int J Clin Exp Pathol 2014; 7: 932-937.
11. [11] Su DH, Chang SH and Chang TC. The impact of locoregional recurrences and distant metastases on the survival of patients with papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2015; 82: 286-294.
12. [12] Karatzas T, Vasileiadis I, Kapetanakis S, Karakostas E, Chrousos G and Kouraklis G. Risk factors contributing to the difference in prognosis for papillary versus micropapillary thyroid carcinoma. Am J Surg 2013; 206: 586-593.
13. [13] Haymart MR, Cayo M and Chen H. Papillary Thyroid Microcarcinomas: Big Decisions for a Small Tumor. Ann Surg Oncol 2009; 16: 3132-3139.
14. [14] Bansal M, Gandhi M, Ferris RL, Nikiforova MN, Yip L, Carty SE and Nikiforov YE. Molecular and histopathologic characteristics of multifocal papillary thyroid carcinoma. Am J Surg Pathol 2013; 37: 1586-1591.
15. [15] Karatzas T, Vasileiadis I, Charitoudis G, Ka-rakostas E, Tseleni-Balafouta S and Kouraklis G. Bilateral versus unilateral papillary thyroid microcarcinoma: predictive factors and associated histopathological findings following total thyroidectomy. Hormones (Athens) 2013; 12: 529-536.
16. [16] Cho SY, Lee TH, Ku YH, Kim HI, Lee GH and Kim MJ. Central lymph node metastasis in papillary thyroid microcarcinoma can be strati fied according to the number, the size of metastatic foci, and the presence of desmoplasia. Surgery 2015; 157: 111-118.
17. [17] Qu H, Sun GR, Liu Y and He QS. Clinical risk factors for central lymph node metastasis in papillary thyroid carcinoma: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 2015; 83: 124-32.
18. [18] Roti E, degli Uberti EC, Bondanelli M and Braverman LE. Thyroid papillary microcarcinoma: a descriptive and meta-analysis study. Eur J Endocrinol 2008; 159: 659-673.
19. [19] Kim HJ, Sohn SY, Jang HW, Kim SW and Chung JH. Multifocality, but not bilaterality, is a predictor of disease recurrence/persistence of papillary thyroid carcinoma. World J Surg 2013; 37: 376-384.
20. [20] Shattuck TM, Westra WH, Ladenson PW and Arnold A. Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. N Engl J Med 2005; 352: 2406-2412.
21. [21] Pellegriti G, Lumera G, Malandrino P, Latina A, Masucci R, Scollo C, Spadaro A, Sapuppo G, Regalbuto C, Pezzino V and Vigneri R. Thyroid cancer in thyroglossal duct cysts requires a specific approach due to its unpredictable extension. J Clin Endocrinol Metab 2013; 98: 458-465.
22. [22] Ito Y, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K and Miyauchi A. Papillary microcarcinoma of the thyroid: how should it be treated? World J Surg 2004; 28: 1115-1121.
23. [23] McDougall IR and Camargo CA. Treatment of micropapillary carcinoma of the thyroid: where do we draw the line? Thyroid 2007; 17: 1093-1096.
24. [24] Dunki-Jacobs E, Grannan K, McDonough S and Engel AM. Clinically unsuspected papillary microcarcinomas of the thyroid: a common finding with favorable biology? Am J Surg 2012; 203: 140-144.
25. [25] Arora N, Turbendian HK, Kato MA, Moo TA, Zarnegar R and Fahey TJ 3rd. Papillary thyroid carcinoma and microcarcinoma: is there a need to distinguish the two? Thyroid 2009; 19: 473-477.
26. [26] Rossi ED, Martini M, Fadda G and Larocca LM. Papillary thyroid microcarcinoma: a painstaking category to manage. Clin Endocrinol (Oxf) 2014; 81: 785-786.
27. [27] Walczyk A, Kowalska A, Kowalik A, Sygut J, Wypiorkiewicz E, Chodurska R, Pieciak L and Gozdz S. The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome? Clin Endocrinol (Oxf) 2014; 80: 899-904.